The Institute is recognized by the National Cancer Institute (NCI) as one of only 51 Comprehensive Cancer Centers in the U.S. This designation signifies that all research, treatment and educational programs meet rigorous national standards and that the Institute has contributed fundamentally to the fight against cancer.
Roswell Park is also a member of the National Comprehensive Cancer Network (NCCN), an alliance of the nation's leading cancer centers. A not-for-profit organization, the NCCN brings together the best minds in science to engineer continuous quality improvements in cancer care, improves the effectiveness of cancer care delivery through the ongoing collection and analysis of outcome data on a national basis, enhances communications and collaboration among member institutions, offers access to the latest, most promising clinical trials, and provides best practice guidelines and measurement tools.
Roswell Park has achieved accreditation from the The Joint Commission (TJC) as a result of its demonstrated compliance with TJC's nationally recognized health care standards.
The innovative quality of our faculty’s research has earned Roswell Park a place among the National Cancer Institute’s top grantees.
- Over the past century, Roswell Park has been the source of historic breakthroughs in the field of oncology.
- Roswell Park initiated the nation’s first chemotherapy research program.
- Roswell Park conducted some of the earliest studies linking smoking to lung cancer.
- Roswell Park developed the PSA test for prostate-cancer screening.
- Roswell Park developed photodynamic therapy (PDT), approved by the FDA for the treatment of esophageal cancer and non-small cell lung cancer, and precancerous lesions in patients with Barrett's esophagus. Roswell Park is now developing the second generation of PDT drugs.
- Roswell Park geneticists created the gene library used to map and sequence the human genome. An Roswell Park geneticist was part of the research team involved in the international effort.